China In Vitro Fertilization market – By Treatment, Forecast 2019-2025
The China in vitro fertilization (IVF) market is expected to register a CAGR of over 14%, during the forecast period, 2019-2025. The major factors driving the market are rising incidence of infertility, technological advancement, and increasing government support.
According to the National Health Commission of the People’s Republic of China, in 2016, around 10% of married Chinese couples were affected by infertility. The IVF procedure comprises of different stages, including ovarian stimulation, egg retrieval, fertilization, embryo transfer, and cryopreservation.
The market is segmented by treatment into intracytoplasmic sperm injection (ICSI), conventional IVF, minimal stimulation IVF, and natural cycle IVF. The conventional IVF segment is further divided into IVF with ovarian hyperstimulation, IVF without ovarian hyperstimulation, and intracytoplasmic sperm injection (ICSI). The minimal stimulation IVF is further classified into microdose gonadotropin and natural cycle IVF.
The market is further segmented by cycle type into fresh IVF cycle and frozen IVF cycle. The fresh IVF cycle is anticipated to hold the largest market share, due to the high success rates associated with this cycle type.
The market is further segmented by end user into fertility clinics, hospitals, and other end users. The fertility clinics segment is further divided into standalone fertility clinics and integrated fertility clinics. The standalone fertility clinics segment is anticipated to hold the largest market share, due to the presence of a large number of such clinics.
Geographically, the market is segmented into five major regions, namely, North China, East China, South China, Central China, and Northwest China.
Some of the prominent players in the China IVF market are BGI, Fujian Tulonghua Human Reproduction Technology Co. Ltd., Hefei Anhui Fertility Clinic, Nanjing Jinling Hospital, and Beijing Obstetrics and Gynecology Hospital.